Investing.com - Mersana Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Mersana Therapeutics announced earnings per share of $-0.61 on revenue of $5.57M. Analysts polled by Investing.com EPS of $0.01 on revenue of $56.78M.
Mersana Therapeutics 's are down 28% and is trading at $7.09 , still down 29.17% from its 52 week high of $10.01 set on Monday, November 8, 2021.
Mersana Therapeutics shares lost 5.97% to trade at $7.09 in intra-day trade the report.
Mersana Therapeutics follows other major Healthcare sector earnings this month
Mersana Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar